Surprise Link Between Menthol And Alzheimer's Found in Mice
In recent years, scientists discovered something strange: When mice with Alzheimer's disease inhale menthol, their cognitive abilities improve.
It seems the chemical compound can stop some of the damage done to the brain that's usually associated with the disease.
In particular, researchers noticed a reduction in the interleukin-1-beta (IL-1β) protein, which helps to regulate the body's inflammatory response – a response that can offer natural protection but one that leads to harm when it's not controlled properly.
The team behind the study, published in April 2023, says it shows the potential for particular smells to be used as therapies for Alzheimer's. If we can figure out which odors cause which brain and immune system responses, we can harness them to improve health.
Watch the video below to see what the scientists discovered:
"We have focussed on the olfactory system's role in the immune and central nervous systems, and we have confirmed that menthol is an immunostimulatory odor in animal models," said immunologist Juan José Lasarte from the Center for Applied Medical Research (CIMA) in Spain when the results were released.
"But, surprisingly, we observed that short exposures to this substance for six months prevented cognitive decline in the mice with Alzheimer's and, what is most interesting, also improved the cognitive ability of healthy young mice."
Having previously observed menthol inhalation boosting the immune response of mice, here the team showed that it could also improve the animals' cognitive abilities, as observed in a series of practical tests in the lab.
In mice with Alzheimer's, the course of menthol for a six-month-long period was enough to stop the cognitive abilities and memory capabilities of the mice from deteriorating. In addition, it appears menthol pushed the IL-1β protein back to safe levels in the brain.
When researchers artificially reduced the number of T regulatory (Treg) cells – known to help keep the immune system in check – some of the same effects were observed, opening a possible route that future treatments could take.
"Both menthol exposure and Treg cell blockade caused a decrease in IL-1β, a protein that could be behind the cognitive decline observed in these models," said neuroscientist Ana Garcia-Osta from CIMA.
"In addition, the specific blockade of this protein with a drug used in treating some autoimmune diseases also improved the cognitive capacity of healthy mice and mice with Alzheimer's."
Scientists have already established numerous links between smells and our immune and nervous systems. These relationships are difficult to fully understand, but we know that our olfactory system can strongly influence the brain.
Certain smells may trigger certain responses in the brain, leading to chemical reactions that affect memory, emotion, and more.
Indeed, diseases related to the central nervous system – such as Alzheimer's, Parkinson's, and schizophrenia – often come with a loss of smell. This new research adds some promising data, but plenty more is needed in humans as well as mice.
"This study is an important step toward understanding the connection between the immune system, the central nervous system, and smell," said immunologist Noelia Casares from CIMA.
"The results suggest that odors and immune modulators may play an important role in the prevention and treatment of Alzheimer's and other diseases related to the central nervous system."
The research was published in Frontiers in Immunology.
An earlier version of this article was published in May 2023.
Scientists Discover West Nile Virus in The UK For The First Time
New Link Connects Herpes to Alzheimer's. Here's What We Know.
Mesmerizing Video Shows Cardiac Cells Building a Heart
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
11 hours ago
- Newsweek
Scientists Map How Alzheimer's Begins in the Brain
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the effects of over 140,000 different versions of proteins, we have created the first comprehensive map of how individual mutations alter the energy landscape of amyloid beta aggregation—a process central to the development of Alzheimer's disease," said paper author and computational biologist Anna Arutyunyan of the Wellcome Sanger Institute in a statement. "Our data-driven model offers the first high-resolution view of the reaction's transition state, opening the door to more targeted strategies for therapeutic intervention," Arutyunyan added. The Alzheimer's Association estimates that some 7.2 million Americans aged 65 and older are presently living with the disease. Its first outward symptom is typically memory problems, but it can lead to delusions, speech issues, disturbed sleep and mood swings. Artist's impression of amyloid-beta peptide buildups within the brain. Artist's impression of amyloid-beta peptide buildups within the brain. selvanegra/iStock / Getty Images Plus At the heart of more than 50 different neurodegenerative diseases is the molecule amyloid beta. This peptide (a chain of amino acids) has a tendency to clump together, forming structures known as amyloid fibrils. In turn, these fibrils gather together into so-called "plaques"—which play a central role in the progression of Alzheimer's disease. The transition from free-flowing amyloid beta to stable fibril structures requires a certain amount of energy—with the peptides having to pass through a "transition state." This state is extremely unlikely to form, accounting for why fibrils and plaques never form in most people. It is also extremely short-lived, which helps account for how difficult it is to study how amyloid beta starts aggregating. Nevertheless, understanding these molecular structures and reactions will be vital for the future development of therapies against Alzheimer's and similar conditions. In the new study, Arutyunyan and colleagues probed the amyloid beta transition by exploring how changing the genetics of the peptide affects its aggregation rate. The team focused on Aβ42, a form of the amyloid beta with 42 amino acids that is commonly found in people with Alzheimer's disease. The researchers used three techniques in their work. First, "massively parallel sequencing" allowed the team to see how changing the amino acids in Aβ42 affects the amount of energy needed to form a fibril. Next, they used genetically engineered yeast cells to measure the rate of the aggregation reaction. Finally, the team used machine learning tools to analyze the results and map out the effect of all the possible mutations of the peptide on fibril formation. In total, the team were able to assess more than 140,000 versions of Aβ42 in one pop—a breakthrough in scale that boosts the accuracy of the resulting models. Read more Map shows states where risk of dementia is highest—are you living in one? Map shows states where risk of dementia is highest—are you living in one? The analysis revealed that only a very few specific interactions between parts of the amyloid beta peptide strongly influenced the rate of fibril formation. Furthermore, the team found that the aggregation reaction begins at one of the tightly packed, water-repellent ends of the peptide, which is known as the C-terminal region. Accordingly, the researchers hope that targeting interactions in this region might allow new means to protect against and treat Alzheimer's disease. "The approach we used in this study opens the door to revealing the structures of other protein transition states, including those implicated in other neurodegenerative diseases," said genomicist professor Ben Lehner, also of the Wellcome Sanger Institute, in a statement. "The scale at which we analyzed the amyloid peptides was unprecedented … we have shown it's a powerful new method to take forward. "We hope this takes us one step closer to developing treatments against Alzheimer's disease and other neurodegenerative conditions," Lehner added. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Alzheimer's disease? Let us know via health@ Reference Arutyunyan, A., Seuma, M., Faure, A. J., Bolognesi, B., & Lehner, B. (2025). Massively parallel genetic perturbation suggests the energetic structure of an amyloid-β transition state. Science Advances, 11 (24).
Indianapolis Star
12 hours ago
- Indianapolis Star
NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment
TAMPA, FL / ACCESS Newswire NeuroEM Therapeutics ®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer's and other neurodegenerative diseases. 'BlueLake's support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer's dementia and other neurodegenerative diseases,' says Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'It fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer's disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.' The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors. He brings over 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo's Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson. 'NeuroEM's pioneering, non-invasive approach to treating and preventing Alzheimer's represents exactly the kind of patented, deep tech innovation we champion at BlueLake – transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades,' said Rutledge. 'We're proud to support the advancement of this groundbreaking technology, and I'm personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.' Adds Papageorgiou, 'Jamie's background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.' NeuroEM Therapeutics, a member of StartUp Health's Alzheimer's Moonshot Community ™, is committed to developing, clinically testing, and marketing its multi-patented TEMT-RF technologies that target and reduce cognitive decline and restore immune balance in the brain and blood while boosting energy production in brain cells – critical elements for optimal cognitive function. Early studies have demonstrated that, as an Alzheimer's treatment, TEMT-RF is safe, enhances cognitive function, and may potentially modify the disease itself. The company's first commercial product, a lightweight cap designed for at-home use, is currently under development and has shown extraordinary promise in preclinical and clinical studies. Worn for an hour twice daily, the device uses short pulses of energy in specific ultra-high frequencies to deliver a transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline. BlueLake Ventures invests in applied deep tech for the future of work and health, technology defined by significant barriers to entry, such as strong patent protection or specialized domain expertise. Its team consists of experienced operators who have built and scaled startup companies, held executive positions in multi-national corporations, built partnerships between startups and corporations, and deployed strategic venture capital in technology-driven businesses. By leveraging its expertise, resources, and networks, BlueLake aims to accelerate the growth of deep tech innovations that empower both businesses and consumers. About NeuroEM Therapeutics ® NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit Media Contact: Liz Goar NPC Creative Services liz@ SOURCE: NeuroEM Therapeutics View the original press release on ACCESS Newswire
Yahoo
12 hours ago
- Yahoo
Cycling Linked to Lower Risk of Dementia, Study of Half a Million Finds
Getting from A to B on a bicycle more often could reduce risk of dementia, possibly by protecting a part of the brain tied to memory functions, new research finds. A study carried out by researchers from the Huazhong University of Science and Technology in China and the University of Sydney backs up the idea that frequent amounts of moderate exercise and keeping the brain busy can guard against neurodegeneration. "The findings of this cohort study suggest an association between active travel mode and incident dementia and brain structure," write the researchers in their published paper. Following UK public health records of nearly half-a-million people aged on average around 56, the researchers looked for a relationship between common forms of transport most and whether individuals developed any form of dementia. The modes of transport were split into four groups: non-active (cars and public transport), walking, walking and non-active combined, and finally a group of people who primarily cycled to get around, or used cycling alongside other options. Commutes to and from work were excluded from the analysis. Compared with non-active travelers, the cyclists had a 19 percent lower risk of all-cause dementia, a 22 percent lower risk of Alzheimer's, a 40 percent lower risk of young-onset dementia (before the age of 65), and a 17 percent lower risk of late-onset dementia. "Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," write the researchers. Dementia is a complex condition, and a whole host of factors are thought to be involved. Previous studies have found a link between spatial navigational abilities and brain volume, for example, which fits in with what the researchers found here: that cyclists ended up with higher hippocampal volumes. It could be the level of physical activity cycling demands that is largely responsible lowering the dementia risk, or having to negotiate routes and directions, or the need to stay alert, or perhaps being more exposed to fresh air. These are all mentioned by the researchers, as is genetic risk – cycling was less beneficial for those with the APOE4 gene variant linked to Alzheimer's. Potentially influential variables like age and education were factored in, but the study doesn't show direct cause and effect – there are plenty of variables that weren't monitored. What it does show is a strong link, which makes sense in the context of other research (associating exercise with dementia risk, for example). What we do know is dementia is a growing issue worldwide, as populations get older. Methods for reducing dementia risk are desperately needed, and cycling could be an easy, affordable option for a lot of people. "Dementia has emerged as a leading contributor to dependence and disability among older adults, with the global number of cases projected to rise from 55 million in 2019 to 139 million by 2050," write the researchers. The research has been published in JAMA Network Open. Scientists Found Cancer in a Dinosaur – And It Might Help Save Human Lives Here's Why Rational People Skip Vaccines Even When They Trust Science Softgel Capsules Draw Concerns Over Toxic Shells. Here's What to Know.
